Successful outpatient parenteral antibiotic therapy delivery via telemedicine

0

High rates of favourable clinical outcomes and likely cost benefits suggest that telemedicine-supported OPAT is an efficacious and safe substitute for inpatient care in our setting” Tan et al (2017).

Abstract:

Objectives: Most outpatient parenteral antimicrobial therapy (OPAT) services use a hospital-based model of care in which patients remain in proximity to large hospitals facilitating clinical review. We aimed to evaluate clinical outcomes and complication rates for patients living in geographically isolated locations managed by telemedicine-supported OPAT.

Methods: This was a retrospective cohort study.

Results: Between 2011 and 2015, we delivered 88 episodes of care involving 83 adult patients resulting in 2261 days of OPAT. The median age was 56 years, 8 of 83 (10%) were indigenous Australian and the median Charlson comorbidity index score was 2 (IQR 1–4). The median distance of patients’ residence from our hospital was 288 km (IQR 201–715) and the median duration on the programme was 26 days (IQR 14–34). Bone and joint infections accounted for 75% of infections treated. Favourable clinical outcomes (improvement or cure) were achieved in 87% of patients and the unplanned, OPAT-related readmission rate was 8%. Nineteen percent and 10% of patients had drug-related and line-related adverse effects, respectively.

Conclusions: Despite a complex case mix, our adverse event and readmission rates are similar to the published literature describing a non-telemedicine model to deliver OPAT. High rates of favourable clinical outcomes and likely cost benefits suggest that telemedicine-supported OPAT is an efficacious and safe substitute for inpatient care in our setting.

Reference:

Tan, S.J., Ingram, P.R., Rothnie, A.J., Whitmore, T.J., Robinson, J.O., Hatch, J.B., Italiano, C.M. and Heath, C.H. (2017) Successful outpatient parenteral antibiotic therapy delivery via telemedicine. Journal of Antimicrobial Chemotherapy, 72(10), p.2898–2901.

https://doi.org/10.1093/jac/dkx203

Thank you to our partners for supporting IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.